Outcome MeasureCognition

MoCA

Montreal Cognitive Assessment

5 Papers in Blossom

Outcome Data Across Studies

Reported results for MoCA across 4 studies with quantitative data.

Outcome data across 14 study arm–timepoint observations
SD
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study
2020Safety
Group therapy + psilocybin(experimental)01827.91.4—
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study
2020Safety
Group therapy + psilocybin(experimental)421828.31.0—
Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)
2022Secondary
Ketamine(experimental)01326.82.0—
Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)
2022Secondary
Ketamine(experimental)11327.41.6—
Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)
2022Secondary
Ketamine(experimental)22827.61.4—
Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)
2022Secondary
Ketamine(experimental)105826.43.1—
Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)
2022Secondary
Midazolam(active_comparator)01227.01.9—
Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)
2022Secondary
Midazolam(active_comparator)11227.81.6—
Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)
2022Secondary
Midazolam(active_comparator)22827.82.2—
Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)
2022Secondary
Midazolam(active_comparator)105828.51.4—

Papers Using MoCA

Paywallindividual

Efficacy and safety of esketamine for smoking cessation among patients diagnosed with lung cancer and major depression disorder: A randomized, placebo-controlled clinical trial

This multicenter, randomised, placebo-controlled clinical trial (n=236) investigates the efficacy and safety of esketamine (ESK) (8x35mg) for smoking cessation in patients with lung cancer and major depressive disorder (MDD). Eight weekly intranasal ESK sessions significantly improved both self-reported (44.1%) and biologically verified (28.8%) smoking abstinence at 6-month follow-up, alongside reductions in depression, anxiety, nicotine dependence, and respiratory symptoms.

Published
Journal
Journal of Affective Disorders
Authors
Hong, C. J.
Paywallindividual

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

In this double‑blind, randomised pilot trial of recently detoxified patients with severe alcohol use disorder and comorbid depression, two 25 mg psilocybin‑assisted psychotherapy sessions (versus 1 mg control) were feasible, acceptable and safe. At 12 weeks the 25 mg group showed higher abstinence (55% vs 11%) and significant reductions in percent drinking days and craving frequency, although blinding was imperfect and the study was small and preliminary.

Published
Journal
Addiction
Authors
Luquiens, A., Belahda, D., Graux, C., Igounenc, N., Serrand, C., Rochefort, P., Mura, T., Sergent, F.
Open Accessindividual

Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program

In a naturalistic open‑label study of 185 adults with severe treatment‑resistant depression, twice‑weekly individually titrated oral esketamine for six weeks significantly reduced depressive symptoms (HDRS‑17 mean 21.2→15.8, p<0.001) with MCID 47.1%, response 26.8% and remission 15.6%, and a low dropout rate (7.6%). Treatment was generally well tolerated with frequent but manageable side effects and no significant urinary or cognitive adverse effects, suggesting oral esketamine is a safe, patient‑friendly option with effectiveness comparable to other administration routes.

Published
Journal
Journal of Psychopharmacology
Authors
Veraart, J. K. E., Smith-Apeldoorn, S. Y., van der Meij, A., Spijker, J., Schoevers, R. A., Kamphuis, J.
Open Accessindividual

Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)

This first pragmatic randomised pilot trial of four once-weekly adjunctive ketamine infusions in hospitalised patients with major depression found the infusions were generally safe and well tolerated but produced no significant difference in HRSD-24 scores versus midazolam. The study indicates a definitive trial of adjunctive ketamine is feasible.

Published
Journal
HRB Open Research
Authors
Gallagher, B., Foley, M., Slattery, C. M., Gusciute, G., Shanahan, E., McLoughlin, D. M.
Open Accessindividual

Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study

This open-label feasibility study (n=17) showed that psilocybin-assisted group therapy (21-25mg/70kg) was safe and effective for the treatment of demoralization in older long-term AIDS survivors.

Published
Journal
EClinicalMedicine
Authors
Anderson, B. T., Danforth, A. L., Daroff, R., Stauffer, C., Ekman, E., Agin-Liebes, G. I., Trope, A., Boden, M. T., Dilley, J., Mitchell, J., Woolley, J. D.

Quick Facts

Full Name
Montreal Cognitive Assessment
Domain
Cognition
Papers Indexed
5
Score Range
0–30
Interpretation
Higher = better
Unit
points
All Measures